Novo Nordisk India, a leading diabetes care company, with a strong presence in haemostasis area, launched a new room temperature stable rFVIIa (NovoSeven) formulation, for Haemophilia with inhibitors. NovoSeven has proven to be effective in the treatment of bleeding in haemophilia patients who develop antibodies (inhibitor patients).
There are approximately 50,000 haemophilia patients in the world of which 3,500 are inhibitor patients. For patients with haemophilia with inhibitors, NovoSeven room temperature stable formulation will provide the confidence to help feel more secure. It has the convenience of speed, safety and simplicity.
Novoseven is a recombinant activated factor seven (rfVIIa), i.e very critical for clot formation in bleeding patients, This Improvised formulation will be available as 1mg/2mg strengths in India that can be used intravenously to stop bleeding in inhibitor patients. A unique feature of NovoSeven is its mechanism of action at the site of vascular injury which results in the formation of a stable fibrin clot that is resistant to breakdown.
NovoSeven room temperature is as effective and safe as earlier formulation with added advantage of being stable at room temperature and reduced injection volume.
NovoSeven room temperature has many safety advantages are that it is a recombinant technology, there is no risk of increased antibodies unlike conventional plasma derived products, low rate of side effects, and Needle-free reconstitution.